Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2012, Article ID 408242, 7 pages
http://dx.doi.org/10.1155/2012/408242
Review Article

Modulating P2X7 Receptor Signaling during Rheumatoid Arthritis: New Therapeutic Approaches for Bisphosphonates

Inflammation and Experimental Surgery Unit, CIBERehd, University Hospital “Virgen de la Arrixaca” and Foundation for Healthcare Training and Research of The Region of Murcia (FFIS), Carretera Madrid-Cartagena s/n, 30120 Murcia, Spain

Received 29 February 2012; Revised 28 May 2012; Accepted 30 May 2012

Academic Editor: Niklas Rye Jørgensen

Copyright © 2012 Alberto Baroja-Mazo and Pablo Pelegrín. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Alamanos, P. V. Voulgari, and A. A. Drosos, “Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review,” Seminars in Arthritis and Rheumatism, vol. 36, no. 3, pp. 182–188, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. D. Guile, L. Alcaraz, T. N. Birkinshaw et al., “Antagonists of the P2X7 receptor. From lead identification to drug development,” Journal of Medicinal Chemistry, vol. 52, no. 10, pp. 3123–3141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. W. P. Maksymowych, “Bisphosphonates—anti-inflammatoy properties,” Current Medicinal Chemistry, vol. 1, pp. 15–28, 2002. View at Publisher · View at Google Scholar
  4. D. V. Novack and S. L. Teitelbaum, “The osteoclast: friend or foe?” Annual Review of Pathology, vol. 3, pp. 457–484, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. A. G. Robling, A. B. Castillo, and C. H. Turner, “Biomechanical and molecular regulation of bone remodeling,” Annual Review of Biomedical Engineering, vol. 8, pp. 455–498, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Burnstock, “Purine and pyrimidine receptors,” Cellular and Molecular Life Sciences, vol. 64, no. 12, pp. 1471–1483, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. W. Grol, N. Panupinthu, J. Korcok, S. M. Sims, and S. J. Dixon, “Expression, signaling, and function of P2X7 receptors in bone,” Purinergic Signalling, vol. 5, no. 2, pp. 205–221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Z. Ke, H. Qi, A. F. Weidema et al., “Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption,” Molecular Endocrinology, vol. 17, no. 7, pp. 1356–1367, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Li, D. Liu, H. Z. Ke, R. L. Duncan, and C. H. Turner, “The P2X7 nucleotide receptor mediates skeletal mechanotransduction,” Journal of Biological Chemistry, vol. 280, no. 52, pp. 42952–42959, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Panupinthu, J. T. Rogers, L. Zhao et al., “P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis,” Journal of Cell Biology, vol. 181, no. 5, pp. 859–871, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Gartland, K. A. Buckley, R. A. Hipskind, W. B. Bowler, and J. A. Gallagher, “P2 receptors in bone—modulation of osteoclast formation and activity via P2X7 activation,” Critical Reviews in Eukaryotic Gene Expression, vol. 13, no. 2–4, pp. 237–242, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Gartland, K. K. Skarratt, L. J. Hocking et al., “Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women,” European Journal of Human Genetics, vol. 20, no. 5, pp. 559–564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. N. R. Jørgensen, L. B. Husted, K. K. Skarratt et al., “Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures,” European Journal of Human Genetics, vol. 20, no. 6, pp. 675–681, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. F. Hiken and T. H. Steinberg, “ATP downregulates P2X7 and inhibits osteoclast formation in RAW cells,” American Journal of Physiology, vol. 287, no. 2, pp. C403–C412, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. D. C. Genetos, D. J. Geist, D. Liu, H. J. Donahue, and R. L. Duncan, “Fluid shear-induced ATP secretion mediates prostaglandin release in MC3T3-E1 osteoblasts,” Journal of Bone and Mineral Research, vol. 20, no. 1, pp. 41–49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Iwamoto, T. Nakamura, A. Doyle et al., “Pannexin 3 regulates intracellular ATP/cAMP levels and promotes chondrocyte differentiation,” Journal of Biological Chemistry, vol. 285, no. 24, pp. 18948–18958, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. M. Knight, S. R. Mcglashan, M. Garcia, C. G. Jensen, and C. A. Poole, “Articular chondrocytes express connexin 43 hemichannels and P2 receptors—a putative mechanoreceptor complex involving the primary cilium?” Journal of Anatomy, vol. 214, no. 2, pp. 275–283, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. K. A. Buckley, S. L. Golding, J. M. Rice, J. P. Dillon, and J. A. Gallagher, “Release and interconversion of P2 receptor agonists by human osteoblast-like cells,” The FASEB Journal, vol. 17, no. 11, pp. 1401–1410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Pellegatti, “A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion,” Molecular Biology of the Cell, vol. 16, no. 8, pp. 3659–3665, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. C. A. Dinarello, “Blocking IL-1 in systemic inflammation,” Journal of Experimental Medicine, vol. 201, no. 9, pp. 1355–1359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. R. R. Hansen, C. K. Nielsen, A. Nasser et al., “P2X7 receptor-deficient mice are susceptible to bone cancer pain,” Pain, vol. 152, no. 8, pp. 1766–1776, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Lopez-Castejon, J. Theaker, P. Pelegrin, A. D. Clifton, M. Braddock, and A. Surprenant, “P2X7 receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases,” Journal of Immunology, vol. 185, no. 4, pp. 2611–2619, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Pelegrin, “Targeting interleukin-1 signaling in chronic inflammation: focus on P2X(7) receptor and Pannexin-1,” Drug News & Perspectives, vol. 21, no. 8, pp. 424–433, 2008. View at Google Scholar · View at Scopus
  24. A. Wesselius, M. J. L. Bours, A. Agrawal et al., “Role of purinergic receptor polymorphisms in human bone,” Frontiers in Bioscience, vol. 16, no. 7, pp. 2572–2585, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. K. L. Sewell and D. E. Trentham, “Pathogenesis of rheumatoid arthritis,” The Lancet, vol. 341, no. 8840, pp. 283–286, 1993. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Burger, J. M. Dayer, G. Palmer, and C. Gabay, “Is IL-1 a good therapeutic target in the treatment of arthritis?” Best Practice and Research, vol. 20, no. 5, pp. 879–896, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. E. H. S. Choy and G. S. Panayi, “Cytokine pathways and joint inflamation in rheumatoid arthritis,” The New England Journal of Medicine, vol. 344, no. 12, pp. 907–916, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. Dayer, B. De Rochemonteix, and B. Burrus, “Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells,” Journal of Clinical Investigation, vol. 77, no. 2, pp. 645–648, 1986. View at Google Scholar · View at Scopus
  29. B. Henderson and E. R. Pettipher, “Comparison of the in vivo inflammatory activities after intra-articular injection of natural and recombinant IL-1α and IL-1β in the rabbit,” Biochemical Pharmacology, vol. 37, no. 21, pp. 4171–4176, 1988. View at Google Scholar · View at Scopus
  30. A. K. Ulfgren, L. Klareskog, and M. Lindberg, “An immunohistochemical analysis of cytokine expression in allergic and irritant contact dermatitis,” Acta Dermato-Venereologica, vol. 80, no. 3, pp. 167–170, 2000. View at Google Scholar · View at Scopus
  31. C. A. Dinarello, “Biologic basis for interleukin-1 in disease,” Blood, vol. 87, no. 6, pp. 2095–2147, 1996. View at Google Scholar · View at Scopus
  32. M. R. Heitmeier, A. L. Scarim, and J. A. Corbett, “Double-stranded RNA-induced inducible nitric-oxide synthase expression and interleukin-1 release by murine macrophages requires NF-κB activation,” Journal of Biological Chemistry, vol. 273, no. 24, pp. 15301–15307, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Bryant and K. A. Fitzgerald, “Molecular mechanisms involved in inflammasome activation,” Trends in Cell Biology, vol. 19, no. 9, pp. 455–464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. L. M. Ryan, J. W. Rachow, and D. J. McCarty, “Synovial fluid ATP: a potential substrate for the production of inorganic pyrophosphate,” Journal of Rheumatology, vol. 18, no. 5, pp. 716–720, 1991. View at Google Scholar · View at Scopus
  35. J. M. Labasi, N. Petrushova, C. Donovan et al., “Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response,” Journal of Immunology, vol. 168, no. 12, pp. 6436–6445, 2002. View at Google Scholar · View at Scopus
  36. F. Caporali, P. L. Capecchi, A. Gamberucci et al., “Human rheumatoid synoviocytes express functional P2X7 receptors,” Journal of Molecular Medicine, vol. 86, no. 8, pp. 937–949, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. S. B. Abramson and A. Amin, “Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage,” Rheumatology, vol. 41, no. 9, pp. 972–980, 2002. View at Google Scholar · View at Scopus
  38. B. Bresnihan, J. M. Alvaro-Gracia, M. Cobby et al., “Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist,” Arthritis and Rheumatism, vol. 41, no. 12, pp. 2196–2204, 1998. View at Google Scholar · View at Scopus
  39. G. D. Kalliolias and S. N. C. Liossis, “The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset still's disease and systemic-onset juvenile idiopathic arthritis,” Expert Opinion on Investigational Drugs, vol. 17, no. 3, pp. 349–359, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Mahamid, R. Mader, and R. Safadi, “Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions,” Clinical Pharmacology, vol. 3, no. 1, pp. 39–43, 2011. View at Google Scholar · View at Scopus
  41. N. Arulkumaran, R. J. Unwin, and F. W. K. Tam, “A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases,” Expert Opinion on Investigational Drugs, vol. 20, no. 7, pp. 897–915, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Andrei, C. Dazzi, L. Lotti, M. R. Torrisi, G. Chimini, and A. Rubartelli, “The secretory route of the leaderless protein interleukin 1β involves exocytosis of endolysosome-related vesicles,” Molecular Biology of the Cell, vol. 10, no. 5, pp. 1463–1475, 1999. View at Google Scholar · View at Scopus
  43. B. J. Gu and J. S. Wiley, “Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor,” Blood, vol. 107, no. 12, pp. 4946–4953, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Hashimoto, H. Kakegawa, Y. Narita et al., “Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis,” Biochemical and Biophysical Research Communications, vol. 283, no. 2, pp. 334–339, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Wang and D. Brömme, “Drug delivery strategies for cathepsin inhibitors in joint diseases,” Expert Opinion on Drug Delivery, vol. 2, no. 6, pp. 1015–1028, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Barbera-Cremades, A. Baroja-Mazo, A. I. Gomez et al., “P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release,” The FASEB Journal, vol. 26, pp. 2951–2962, 2012. View at Google Scholar
  47. A. J. Roelofs, K. Thompson, S. Gordon et al., “Molecular mechanisms of action of bisphosphonates: current status,” Clinical Cancer Research, vol. 12, no. 20, pp. 6222s–6230s, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. M. J. Rogers, J. C. Frith, S. P. Luckman et al., “Molecular mechanisms of action of bisphosphonates,” Bone, vol. 24, supplement 5, pp. 73S–79S, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. M. J. Rogers, S. Gordon, H. L. Benford et al., “Cellular and molecular mechanisms of action of bisphosphonates,” Cancer, vol. 88, supplement 12, pp. 2961–2978, 2000. View at Google Scholar · View at Scopus
  50. J. D. Adachi, W. P. Olszynski, D. A. Hanley et al., “Management of corticosteroid-induced osteoporosis,” Seminars in Arthritis and Rheumatism, vol. 29, no. 4, pp. 228–251, 2000. View at Google Scholar · View at Scopus
  51. E. S. Siris, “Goals of treatment for Paget's disease of bone,” Journal of Bone and Mineral Research, vol. 14, supplement 2, pp. 49–52, 1999. View at Google Scholar · View at Scopus
  52. N. Van Rooijen and A. Sanders, “Liposome mediated depletion of macropbages: mechanism of action, preparation of liposomes and applications,” Journal of Immunological Methods, vol. 174, no. 1-2, pp. 83–93, 1994. View at Google Scholar · View at Scopus
  53. J. C. Frith, J. Mönkkönen, G. M. Blackburn, R. G. G. Russell, and M. J. Rogers, “Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro,” Journal of Bone and Mineral Research, vol. 12, no. 9, pp. 1358–1367, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. J. C. Frith, J. Mönkkönen, S. Auriola, H. Mönkkönen, and M. J. Rogers, “The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis,” Arthritis and Rheumatism, vol. 44, no. 9, pp. 2201–2210, 2001. View at Google Scholar · View at Scopus
  55. P. P. Lehenkari, M. Kellinsalmi, J. P. Näpänkangas et al., “Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite,” Molecular Pharmacology, vol. 61, no. 5, pp. 1255–1262, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. F. P. Coxon, K. Thompson, and M. J. Rogers, “Recent advances in understanding the mechanism of action of bisphosphonates,” Current Opinion in Pharmacology, vol. 6, no. 3, pp. 307–312, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. M. L. Tiku, J. B. Liesch, and F. M. Robertson, “Production of hydrogen peroxide by rabbit articular chondrocytes. Enhancement by cytokines,” Journal of Immunology, vol. 145, no. 2, pp. 690–696, 1990. View at Google Scholar · View at Scopus
  58. K. Bauerova and A. Bezek, “Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis,” General Physiology and Biophysics, vol. 18, pp. 15–20, 1999. View at Google Scholar · View at Scopus
  59. R. Serretti, P. Core, S. Muti, and F. Salaffi, “Influence of dichloromethylene diphosphonate on reactive oxygen species production by human neutrophils,” Rheumatology International, vol. 13, no. 4, pp. 135–138, 1993. View at Publisher · View at Google Scholar · View at Scopus
  60. E. J. Dombrecht, C. B. De Tollenaere, K. Aerts et al., “Antioxidant effect of bisphosphonates and simvastatin on chondrocyte lipid peroxidation,” Biochemical and Biophysical Research Communications, vol. 348, no. 2, pp. 459–464, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Pelegrin and A. Surprenant, “Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates,” The EMBO Journal, vol. 28, no. 14, pp. 2114–2127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Lopez-Castejón, A. Baroja-Mazo, and P. Pelegrín, “Novel macrophage polarization model: from gene expression to identification of new anti-inflammatory molecules,” Cellular and Molecular Life Sciences, vol. 68, no. 18, pp. 3095–3107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. H. Zimmermann, “Extracellular metabolism of ATP and other nucleotides,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 362, no. 4-5, pp. 299–309, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. A. M. Ho, M. D. Johnson, and D. M. Kingsley, “Role of the mouse ank gene in control of tissue calcification and arthritis,” Science, vol. 289, no. 5477, pp. 265–270, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. S. C. Sun and S. C. Ley, “New insights into NF-κB regulation and function,” Trends in Immunology, vol. 29, no. 10, pp. 469–478, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Gloire and J. Piette, “Redox regulation of nuclear post-translational modifications during NF-κB activation,” Antioxidants and Redox Signaling, vol. 11, no. 9, pp. 2209–2222, 2009. View at Publisher · View at Google Scholar · View at Scopus